-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 23, Cansino announced that it had obtained the "Drug Registration Certificate" issued by the State Food and Drug Administration for the Group A and C Meningococcal Polysaccharide Conjugate Vaccine
Meningococcal disease is a serious infectious disease mainly caused by Neisseria meningitidis, with the highest incidence among infants and young children under 12 months of age
The main meningococcal vaccine in China is meningococcal polysaccharide vaccine (MPSV), including MPSV2 and MPSV4
The company's MCV2 has completed phase I and phase III clinical trials, and the phase I clinical results initially show that the company's MCV2 has good safety and tolerability in various age groups